186 related articles for article (PubMed ID: 27863726)
1. [MET receptor inhibition: Hope against resistance to targeted therapies?].
Hochart A; Leblond P; Le Bourhis X; Meignan S; Tulasne D
Bull Cancer; 2017 Feb; 104(2):157-166. PubMed ID: 27863726
[TBL] [Abstract][Full Text] [Related]
2. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Robinson KW; Sandler AB
Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
[TBL] [Abstract][Full Text] [Related]
3. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.
Kwak EL; Ahronian LG; Siravegna G; Mussolin B; Borger DR; Godfrey JT; Jessop NA; Clark JW; Blaszkowsky LS; Ryan DP; Lennerz JK; Iafrate AJ; Bardelli A; Hong TS; Corcoran RB
Cancer Discov; 2015 Dec; 5(12):1271-81. PubMed ID: 26432108
[TBL] [Abstract][Full Text] [Related]
4. Advances in anti-BRAF therapies for lung cancer.
Roviello G; D'Angelo A; Sirico M; Pittacolo M; Conter FU; Sobhani N
Invest New Drugs; 2021 Jun; 39(3):879-890. PubMed ID: 33474634
[TBL] [Abstract][Full Text] [Related]
5. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.
Oddo D; Siravegna G; Gloghini A; Vernieri C; Mussolin B; Morano F; Crisafulli G; Berenato R; Corti G; Volpi CC; Buscarino M; Niger M; Dunne PD; Rospo G; Valtorta E; Bartolini A; Fucà G; Lamba S; Martinetti A; Di Bartolomeo M; de Braud F; Bardelli A; Pietrantonio F; Di Nicolantonio F
Br J Cancer; 2017 Jul; 117(3):347-352. PubMed ID: 28654634
[TBL] [Abstract][Full Text] [Related]
6. Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.
Della Corte CM; Fasano M; Papaccio F; Ciardiello F; Morgillo F
Biomedicines; 2014 Nov; 2(4):345-358. PubMed ID: 28548075
[TBL] [Abstract][Full Text] [Related]
7. Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Drilon A; Cappuzzo F; Ou SI; Camidge DR
J Thorac Oncol; 2017 Jan; 12(1):15-26. PubMed ID: 27794501
[TBL] [Abstract][Full Text] [Related]
8. Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.
Forde PM; Kelly RJ
Oncologist; 2013; 18(7):823-32. PubMed ID: 23853247
[TBL] [Abstract][Full Text] [Related]
9. Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
Jabbarzadeh Kaboli P; Chen HF; Babaeizad A; Roustai Geraylow K; Yamaguchi H; Hung MC
Cancer Lett; 2024 Apr; 588():216780. PubMed ID: 38462033
[TBL] [Abstract][Full Text] [Related]
10. Recording and classifying MET receptor mutations in cancers.
Guérin C; Tulasne D
Elife; 2024 Apr; 13():. PubMed ID: 38652103
[TBL] [Abstract][Full Text] [Related]
11. Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation.
Virzì AR; Gentile A; Benvenuti S; Comoglio PM
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):10058-10063. PubMed ID: 30224486
[TBL] [Abstract][Full Text] [Related]
12. The influence of subclonal resistance mutations on targeted cancer therapy.
Schmitt MW; Loeb LA; Salk JJ
Nat Rev Clin Oncol; 2016 Jun; 13(6):335-47. PubMed ID: 26483300
[TBL] [Abstract][Full Text] [Related]
13. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.
Smyth EC; Sclafani F; Cunningham D
Onco Targets Ther; 2014; 7():1001-14. PubMed ID: 24959087
[TBL] [Abstract][Full Text] [Related]
14. Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates.
Powers AD; Liu B; Lee AG; Palecek SP
Analyst; 2012 Sep; 137(17):4052-61. PubMed ID: 22814332
[TBL] [Abstract][Full Text] [Related]
15. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis.
Liang H; Wang M
Onco Targets Ther; 2020; 13():2491-2510. PubMed ID: 32273721
[TBL] [Abstract][Full Text] [Related]
16. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.
Gonzalez de Castro D; Clarke PA; Al-Lazikani B; Workman P
Clin Pharmacol Ther; 2013 Mar; 93(3):252-9. PubMed ID: 23361103
[TBL] [Abstract][Full Text] [Related]
17. Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.
Huang X; Li E; Shen H; Wang X; Tang T; Zhang X; Xu J; Tang Z; Guo C; Bai X; Liang T
Front Cell Dev Biol; 2020; 8():152. PubMed ID: 32435640
[TBL] [Abstract][Full Text] [Related]
18. Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer.
Zhuang H; Zhao X; Zhao L; Chang JY; Wang P
Drug Des Devel Ther; 2014; 8():667-75. PubMed ID: 24936128
[TBL] [Abstract][Full Text] [Related]
19. MET overexpression and gene amplification in NSCLC: a clinical perspective.
Landi L; Minuti G; D'Incecco A; Salvini J; Cappuzzo F
Lung Cancer (Auckl); 2013; 4():15-25. PubMed ID: 28210131
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I.
Combarel D; Dousset L; Bouchet S; Ferrer F; Tetu P; Lebbe C; Ciccolini J; Meyer N; Paci A
Crit Rev Oncol Hematol; 2024 May; 199():104384. PubMed ID: 38762217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
